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Abstract 
 Background: Comorbidities can affect survival of ovarian cancer patients by influencing 
treatment efficacy. However, little evidence exists on the association between individual 
concurrent comorbidities and prognosis in ovarian cancer patients.  
Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 
studies included in the Ovarian Cancer Association Consortium, we explored associations 
between histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, 
gallbladder, kidney, liver and neurological diseases and overall and progression-free survival. 
Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, 
histology, and study site, we estimated pooled hazard ratios and 95% confidence intervals to 
assess associations between each comorbidity and ovarian cancer outcomes.  
Results:  None of the comorbidities were associated with ovarian cancer outcome in the overall 
sample nor in strata defined by histological subtype, weight status, age at diagnosis or stage of 
disease (local/regional vs. advanced). 
Conclusions:  Histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, 
gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall 
or progression-free survival.  
Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer 
prognosis.
Introduction 
Preexisting chronic diseases among ovarian cancer patients can results in the use of 
nonstandard treatment regimens (1) or intolerance to the standard treatments (2), therefore, 
limiting cancer therapy or affecting prognosis in these patients (3). Despite the likely role of 
comorbidities in ovarian cancer prognosis, detailed evidence regarding associations with 
particular comorbidities is limited, and results of earlier studies conducted to explore such 
associations are not consistent (1-6). These studies either did not distinguish among individual 
comorbidities or had insufficient statistical power to examine associations, particularly for 
histological subtypes.  
Previously we reported on the association between histories of hypertension, heart 
disease, and diabetes in relation to overall survival (OS) and progression-free survival (PFS) 
among ovarian cancer patients (7). In this study, using a large multi-national sample of studies 
participating in the Ovarian Cancer Association Consortium (OCAC), we explore the 
relationship between other selected common comorbidities and OS and PFS among women 
diagnosed with ovarian cancer. We hypothesize that these comorbidities are associated with poor 
ovarian cancer prognosis.  
 
Materials and methods 
Our analyses use pooled data from 23 studies. Characteristics of the included studies 
included are shown in Table 1. Patient-related data were collected by either self- or interviewer-
administered questionnaires and/or medical records reviews. These data were obtained from the 
participating study centers, cleaned, and harmonized. Comorbidities of interest comprise 
endometriosis, asthma, autoimmune diseases (dermatomyositis, polymyositis, rheumatoid 
arthritis, Sjögren’s syndrome, scleroderma, systemic lupus erythematosus, inflammatory bowel 
disease, Hashimoto’s disease, Grave’s disease, and Type I diabetes), depression/anxiety, 
osteoporosis, and any kidney, liver, gallbladder, and neurological diseases. For the analyses, the 
study sample was limited to women with invasive epithelial ovarian cancer and no missing 
information on vital status, length of follow up at the time of last contact or the comorbidity of 
interest (varies for each disease).  
 We used age-, stage-, histology-, and site-adjusted Cox proportional hazards models to 
explore associations between each comorbidity and ovarian cancer outcomes by calculating  
pooled hazards ratios (HRs) and their 95% confidence intervals (CIs). We were not able to assess 
heterogeneity among study-specific HRs due to limited numbers of cases in some studies. No 
other etiologically or prognostically important available factors appreciably changed observed 
estimates of age- and stage-adjusted study-specific or overall HRs; therefore, they were not 
included in any of the models.  
In all the models, overall survival (OS) was defined as the time from the date of diagnosis 
to the date of death or end of follow up, whichever occurred first. Progression-free survival 
(PFS) was defined as the time from the date of diagnosis to the date when progression status 
(persistence, recurrence, or death) was determined, or the end of follow-up for cases without 
identified progression. Cases with no history of the comorbidity of interest were the referent. 
 We also examined whether or not associations differed according to the main histological 
subtypes (high-grade serous, low-grade serous, mucinous, endometrioid, and clear cell), 
overweight status (18.5 kg/m
2
<body mass index (BMI)<25.0 kg/m
2
 vs. BMI≥25.0 kg/m2), age at 
diagnosis (<65 vs. ≥65 years), and stage of disease (local/regional vs. advanced). In addition, we 
examined possible multiplicative interactions by likelihood ratio statistics.  
  We had 80% power to detect the following risk estimates for OS and PFS respectively: 
1.11 and 1.20 for endometriosis, 1.28 and 1.34 for asthma, 1.15 and 1.23 for depression, 1.26 and 
1.41 for osteoporosis, 1.22 and 1.27 for autoimmune disease, 1.50 and 1.95 for kidney disease, 
1.71 and 1.97 for liver disease, 1.16 and 1.21 for gallbladder disease, and 2.08 and 2.29 for 
neurological diseases. 
 
Results  
Results of the analyses are presented in Table 2. No significant associations were 
observed between histories of endometriosis, asthma, depression, osteoporosis, autoimmune, 
gallbladder, kidney, liver, and neurological diseases and OS or PFS. Results were also not 
significant and not different in strata defined by histological subtype, overweight status, age, and 
stage of disease. No evidence of multiplicative interaction was observed.  
 
Discussion  
 In this large international sample of women diagnosed with invasive ovarian cancer, we 
did not observe associations between histories of endometriosis, asthma, depression, 
osteoporosis, and autoimmune, kidney, liver, gallbladder, and neurological diseases and OS and 
PFS. Results of our study are similar to others reporting no association between presence of 
comorbidity and survival among ovarian cancer patients (1, 4, 6). Our results are also consistent 
with those from Hemminki et al.(8) that showed no association between autoimmune disease and 
OS, HR=1.09 (95% CI:0.99-1.20). These results suggest that various comorbidities have little 
impact on survival for a disease that is already characterized by poor prognosis (4). 
 Strengths of our study include the large sample of patients with ovarian cancer, allowing 
for the assessment of associations within histological subtypes as well as potential effect 
modification. Limitations of this research includes the possibility of residual confounding, 
particularly due to the absence of information on treatment regimen and on comorbidities 
diagnosed after ovarian cancer diagnosis.  
In conclusion, we did not observe evidence of the relationship between selected chronic 
diseases and OS and PFS among cases diagnosed with invasive epithelial ovarian carcinoma.   
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 Table 1. Characteristics of studies included in the analysis: Ovarian Cancer Association Consortium 
1
. 
Study 
acron
ym 
Study name Study 
location, 
year of 
diagnosis 
Data 
collection 
method 
Endometriosis Asthma Auto 
immune 
Depression Osteo- 
porosis 
Gallbladder 
disease 
Kidney 
disease 
Liver 
disease 
Neurologi
cal disease 
AOV Alberta Ovarian 
Tumor Types Study 
Canada 1978-
2010 
MRR MRR: reporting 
of disease 
- - - - - - - - 
AUS
2 
Australian Ovarian 
Cancer Study 
Australia 
2002-2006 
Self-completed 
questionnaire 
Q:Ever having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
BAV
2
 Bavarian Ovarian 
Cancer Cases and 
Controls 
Germany 
2002-2006 
In-person 
interview 
Q: disease 
found during 
surgery 
- - - - - - - - 
CON Connecticut 
Ovarian Cancer 
Study 
USA: CT 
1998-2003 
In-person 
interview 
Q:Disease 
diagnosed by 
physician 
- - - - - - - - 
DOV Disease of the 
Ovary and their 
Evaluation Study 
USA: WA 
2002-2005 
(DOV) 
2006-2009 
(DVE) 
In-person 
interview 
Q:Disease 
diagnosed by 
physician 
- Q:Disease 
diagnosed 
by 
physician 
- - - - - - 
GER German Ovarian 
Cancer Study 
Germany 
1993-1996 
Self-
administered 
questionnaire 
Q:Disease 
diagnosed by 
physician 
- - - - Q:Disease 
diagnosed by 
physician 
- - - 
HAW
2 
Hawaii Ovarian 
Cancer Study 
USA: HI 
1993-2008 
In-person 
interview 
Q:Disease 
diagnosed by 
physician 
- Q:Disease 
diagnosed 
by 
physician 
Q:Disease 
diagnosed by 
physician 
- - - - - 
HJO
2
 Hannover-Jena 
Ovarian Cancer 
Study 
Germany 
2007-2011 
MRR MRR: reporting 
of disease 
 MRR: 
reporting of 
disease 
  MRR: 
reporting of 
disease 
   
HOP
2 
Hormones and 
Ovarian Cancer 
Prediction Study 
USA: PA, 
OH, and NY 
2003-2009 
In-person 
interview, 
MRR 
Q:Ever having 
disease; 
MRR: reporting 
of disease 
Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting 
of disease 
Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting of 
disease 
MRR: 
reporting of 
disease 
MRR: 
reporting 
of disease 
MRR: 
reporting of 
disease 
MRR: 
reporting 
of disease 
MRR: 
reporting 
of disease 
MRR: 
reporting 
of disease 
JPN
2 
Hospial-based 
Research Program 
at Aichi Cancer 
Center 
Japan 
2001-2005 
In-person 
interview 
Q:Ever having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever  
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
LAX
2 
Women's Cancer 
Program at the 
Samuel Oschin 
Comprehensive 
USA:  CA 
1989-present 
 
 
MRR MRR: reporting 
of disease 
- MRR: 
reporting of 
disease 
- - MRR: 
reporting of 
disease 
- - - 
Cancer Institute 
MAC
2
 
Mayo Clinic Case-
Only Ovarian 
Cancer Study 
USA 
2000-2011 
Self-completed 
questionnaire 
Q:Ever 
diagnosed with 
disease 
- - - - - - - - 
MAL
2 
MALignant 
OVArian cancer 
 
 
Denmark 
1994-1999 
 
 
In-person 
interview 
Q:Disease 
diagnosed by 
physician 
Q:Determi
ned based 
on 
medication 
intake 
Q:Disease 
diagnosed 
by 
physician 
Q:Determine
d based on 
medication 
intake 
Q:Disease 
diagnosed 
by 
physician 
- - Q:Disease 
diagnosed 
by 
physician 
- 
MAY
2
 
Mayo Clinic 
Ovarian Cancer 
Case-Control Study 
 
USA: MN, 
SD, ND, IL, 
IA, WI 
2003-2009 
In-person 
interview 
Q:Ever 
diagnosed with 
disease 
- - - - - - - - 
NCO
2 
North Carolina 
Ovarian Cancer 
Study 
USA: NC Self-completed 
questionnaire 
Q:Disease 
diagnosed by 
physician 
- Q:Disease 
diagnosed 
by 
physician 
Q:Disease 
diagnosed by 
physician 
Q:Disease 
diagnosed 
by 
physician 
Q:Disease 
diagnosed by 
physician 
- - - 
NEC
2 
New England Case-
Control Study of 
Ovarian Cancer 
USA:NH and 
MA 
1992-2003 
In-person 
interview 
Q:Ever having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
Q:Ever 
having 
disease 
NJO New Jersey Ovarian 
Cancer Study 
 
 
USA: NJ 
2002-2008 
 
 
Phone 
interview 
Q:Disease 
diagnosed by 
physician 
- Q:Disease 
diagnosed 
by 
physician 
Q:Disease 
diagnosed by 
physician 
Q:Disease 
diagnosed 
by 
physician 
- - - Q:Disease 
diagnosed 
by 
physician 
NTH 
Nijmegen Ovarian 
Cancer Study 
 
 
 
Netherlands 
1989-2006 
 
 
Self-completed 
questionnaires 
MRR 
Q:Disease 
diagnosed by 
physician 
MRR: reporting 
of disease 
Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting 
of disease 
Q: Disease 
diagnosed 
by 
physician 
- Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting 
of disease 
- Q:Diseas
e 
diagnose
d by 
physician 
MRR: 
reporting 
of disease 
Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting 
of disease 
Q:Disease 
diagnosed 
by 
physician 
MRR: 
reporting 
of disease 
TBO Tampa Bay Ovarian 
Cancer Study 
 
USA:FL 
2000-present 
Self-completed 
questionnaires 
Q:Disease 
diagnosed by 
physician 
- - - - - -- - - 
UCI University of 
California, Irvine 
Ovarian Cancer 
Study 
USA: CA 
1995-2005 
 
 
Self-completed 
questionnaires 
Q:Disease 
diagnosed by 
physician 
- - - - - - - - 
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2 
Studies that provided information on progression-free survival 
Abbreviations used: MRR-medical records review, Q-question. 
 Table 2. Associations between history of selected comorbidities and overall and progression-free 
survival: Ovarian Cancer Association Consortium. 
Comorbidity Deceased HR(95% CI)
1,2 
Progression HR(95% CI)
1,2 
 Yes No Yes No 
Endometriosis 
No 
Yes 
 
6356 
571 
 
4824 
853 
 
1.00(ref) 
0.92(0.84-1.01) 
 
2554 
203 
 
1329 
184 
 
1.00(ref) 
1.06(0.91-1.24) 
Asthma 
No 
Yes 
 
2117 
125 
 
1393 
101 
 
1.00(ref) 
1.00(0.84-1.20) 
 
1446 
89 
 
640 
50 
 
1.00(ref) 
0.93(0.75-1.16) 
Depression 
No 
Yes 
 
2731 
439 
 
1647 
308 
 
1.00(ref) 
0.97(0.87-1.08) 
 
1669 
202 
 
741 
98 
 
1.00(ref) 
0.90(0.76-1.07) 
Osteoporosis 
No 
Yes 
 
2043 
170 
 
1405 
85 
 
1.00(ref) 
0.95(0.81-1.12) 
 
1093 
76 
 
445 
21 
 
1.00(ref) 
0.96(0.73-1.27) 
Autoimmune disease 
No 
Yes 
 
907 
242 
 
579 
178 
 
1.00(ref) 
0.94(0.73-1.22) 
 
784 
162 
 
386 
76 
 
1.00(ref) 
0.95(0.74-1.23) 
Kidney disease 
No 
Yes 
 
1739 
48 
 
1317 
37 
 
1.00(ref) 
1.19(0.89-1.60) 
 
1004 
18 
 
516 
9 
 
1.00(ref) 
1.04(0.65-1.67) 
Liver disease 
No 
Yes 
 
2186 
31 
 
1461 
15 
 
1.00(ref) 
0.98(0.68-1.41) 
 
1485 
15 
 
664 
10 
 
1.00(ref) 
0.86(0.54-1.38) 
Gallbladder  disease 
No 
Yes 
 
2433 
438 
 
1626 
205 
 
1.00(ref) 
1.06(0.96-1.18) 
 
1483 
254 
 
645 
88 
 
1.00(ref) 
1.09(0.94-1.26) 
Neurological disease 
No 
Yes 
 
1156 
17 
 
1031 
11 
 
1.00(ref) 
1.32(0.79-2.21) 
 
547 
9 
 
250 
8 
 
1.00(ref) 
0.82(0.41-1.68) 
1
 models adjusted for age (continuous), stage (localized, regional, or advanced), histology, and study site 
2
 studies included for each comorbidity as presented in Table 1 
 
